{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-047735","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2026-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.611567+00:00","generated_at":"2026-05-15T04:34:27.981972+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Corvus Pharmaceuticals appoints Andrew C. Chan to board; Scott Morrison resigns","bullets":["Andrew C. Chan appointed as Class II director, effective April 23, 2026, term through 2027 annual meeting.","Chan receives $35,000 annual retainer, $4,000 Nominating Committee fee, and initial option for 30,000 shares.","Scott Morrison resigned from board effective April 23, 2026 after over a decade of service.","Chan also appointed to the Nominating Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-047735","json":"https://secwatch.observer/filing/0001104659-26-047735.json","markdown":"https://secwatch.observer/filing/0001104659-26-047735.md","text":"https://secwatch.observer/filing/0001104659-26-047735.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000110465926047735/0001104659-26-047735-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000110465926047735/crvs-20260422x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:34:27.981972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}